A phase I dose ranging study of the safety, tolerability and immunogenicity of a 3-dose regimen of the MRKAd5 HIV-1 trigene [V 520] and the MRKAd6 HIV-1 trigene [V 526] vaccines alone and in combination in healthy adults.

Trial Profile

A phase I dose ranging study of the safety, tolerability and immunogenicity of a 3-dose regimen of the MRKAd5 HIV-1 trigene [V 520] and the MRKAd6 HIV-1 trigene [V 526] vaccines alone and in combination in healthy adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2014

At a glance

  • Drugs V 520 (Primary) ; V 526 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms COMPLETED
  • Sponsors Merck & Co
  • Most Recent Events

    • 26 Feb 2009 Status changed from not stated to active, no longer recruiting.
    • 24 Feb 2009 New source identified and integrated (ClinicalTrials.gov); planned end date is 1 Mar 2011.
    • 20 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top